Клинический опыт применения идаруцизумаба перед проведением тромболитической терапии инфаркта мозга в Свердловской области

Abstract

Introduction. In recent years, the use of oral anticoagulants for the prevention of ischemic strokes (IS) in patients with atrial fibrillation (AF), as well as the prevention of deep vein thrombosis and thromboembolism has been increasing in clinical practice. According to epidemiological studies, ischemic strokes account for about 85% of all AMI. Cardioembolic strokes (CES), which develop due to embolism to the cerebral vessels from the heart chambers, deserve special attention. The presence of AF is associated with a twofold increase in the risk of death from cardiovascular disease and death from any cause. Timely anticoagulant therapy can reduce the risk of thromboembolic complications and improve the prognosis.

Цель исследования — демонстрация клинического опыта применения идаруцизумаба для нейтрализации антикоагулянтного эффекта дабигатрана у пациентки с ИИ перед выполнением ТЛТ